Corvus Pharmaceuticals Inc (CRVS)

10:13 AM

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025 - The Manila Times

10:13 AM

10:10 AM

Corvus Pharmaceuticals Presents Promising Interim Data for Ciforadenant in Combination Therapy for Metastatic Renal Cell Carcinoma at ESMO Congress 2025 - Quiver Quantitative

10:10 AM

10:00 AM

34% deep response: Corvus triplet posts 46% ORR and 11.04-month PFS in Phase 1b/2 RCC - Stock Titan

10:00 AM

03:38 AM

Will Corvus Pharmaceuticals Inc. stock go up soon2025 Price Action Summary & Real-Time Price Movement Reports - newser.com

03:38 AM

Oct 16, 2025

Key resistance and support levels for Corvus Pharmaceuticals Inc.Bull Run & Fast Exit/Entry Strategy Plans - newser.com

Oct 16, 2025

Oct 15, 2025

Corvus Pharmaceuticals, Inc.Common Stock (Nasdaq:CRVS) Stock Quote | Dow Theory Letters - FinancialContent

Oct 15, 2025

Oct 15, 2025

Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected - MSN

Oct 15, 2025

Oct 15, 2025

What technical models suggest about Corvus Pharmaceuticals Inc.’s comebackQuarterly Trade Summary & Weekly Sector Rotation Insights - newser.com

Oct 15, 2025

Oct 13, 2025

Should you hold or exit Corvus Pharmaceuticals Inc. nowPortfolio Update Report & Daily Profit Focused Stock Screening - newser.com

Oct 13, 2025

Oct 13, 2025

Using RSI to spot recovery in Corvus Pharmaceuticals Inc.July 2025 News Drivers & Entry and Exit Point Strategies - newser.com

Oct 13, 2025

Oct 13, 2025

Barclays Initiates Corvus Pharmaceuticals at Overweight With $16 Price Target - MarketScreener

Oct 13, 2025

Oct 13, 2025

Barclays Initiates Coverage on CRVS with Overweight Rating | CRV - GuruFocus

Oct 13, 2025

Oct 13, 2025

Barclays initiates Corvus Pharmaceuticals stock with Overweight rating - Investing.com

Oct 13, 2025

Oct 13, 2025

Barclays initiates Corvus Pharmaceuticals stock with Overweight rating By Investing.com - Investing.com UK

Oct 13, 2025

Oct 10, 2025

Corvus Pharmaceuticals Inc.’s volatility index tracking explainedShort Setup & Safe Entry Momentum Stock Tips - newser.com

Oct 10, 2025

Oct 10, 2025

What analysts say about Corvus Pharmaceuticals Inc stockInsider Trading Activity & Free Lightning Fast Capital Gains - earlytimes.in

Oct 10, 2025

Oct 10, 2025

Weiss Ratings Reaffirms "Sell (D-)" Rating for Corvus Pharmaceuticals (NASDAQ:CRVS) - MarketBeat

Oct 10, 2025

Oct 06, 2025

CRVS Form 3 — Director David Moore files initial report with no securities - Stock Titan

Oct 06, 2025

Oct 06, 2025

Detecting support and resistance levels for Corvus Pharmaceuticals Inc.July 2025 Momentum & Verified Momentum Watchlists - newser.com

Oct 06, 2025

Oct 06, 2025

Empirical Financial Services LLC d.b.a. Empirical Wealth Management Invests $672,000 in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat

Oct 06, 2025

Oct 05, 2025

Has Corvus Pharmaceuticals Inc. formed a bullish divergenceJuly 2025 Reactions & Breakout Confirmation Trade Signals - newser.com

Oct 05, 2025

Oct 03, 2025

Published on: 2025-10-03 06:35:03 - newser.com

Oct 03, 2025

Oct 03, 2025

Measuring Corvus Pharmaceuticals Inc.’s beta against major indicesEarnings Miss & Community Verified Trade Signals - newser.com

Oct 03, 2025

Oct 03, 2025

Chart based exit strategy for Corvus Pharmaceuticals Inc.July 2025 Macro Moves & Advanced Technical Signal Analysis - newser.com

Oct 03, 2025

Oct 03, 2025

Candlestick signals on Corvus Pharmaceuticals Inc. stock todayWall Street Watch & Daily Stock Trend Watchlist - newser.com

Oct 03, 2025

Oct 02, 2025

Corvus Pharmaceuticals appoints David Moore to board of directors - Investing.com

Oct 02, 2025

Oct 02, 2025

Corvus Pharmaceuticals Appoints David Moore To Board Of Directors - TradingView

Oct 02, 2025

Oct 02, 2025

Novo Nordisk EVP David Moore Joins Corvus Board to Advance ITK Inhibitor Platform and Commercial Strategy - Stock Titan

Oct 02, 2025

Oct 01, 2025

Published on: 2025-10-01 07:08:07 - newser.com

Oct 01, 2025

Sep 28, 2025

What drives Corvus Pharmaceuticals Inc stock priceStock Rotation Strategies & Low Risk Capital Appreciation - earlytimes.in

Sep 28, 2025

Sep 27, 2025

Is Corvus Pharmaceuticals Inc a good long term investmentRisk-Reward Ratio Analysis & Tap Into the Fastest-Growing Companies - Early Times

Sep 27, 2025

Sep 26, 2025

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 6.1%Should You Buy? - MarketBeat

Sep 26, 2025

Sep 25, 2025

Are Investors Undervaluing Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) By 37%? - 富途牛牛

Sep 25, 2025

Sep 25, 2025

While institutions invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) benefited from last week's 12% gain, individual investors stood to gain the most - simplywall.st

Sep 25, 2025

Sep 23, 2025

Is Corvus Pharmaceuticals Inc. trending in predictive chart modelsMarket Growth Report & Growth Oriented Trade Recommendations - newser.com

Sep 23, 2025

Sep 22, 2025

What candlestick patterns are forming on Corvus Pharmaceuticals Inc.Weekly Profit Report & Free Daily Entry Point Trade Alerts - newser.com

Sep 22, 2025